Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26
| Autor: | Eric Xueyu Chen, Jonathan M. Loree, Dongsheng Tu, Christopher J. O'Callaghan, Hagen Fritz Kennecke, Derek J. Jonker, Ahmad Chaudhary, Bruce Colwell, Mohammed Harb, Nathalie Aucoin, Felix Couture, Setareh Samimi, Petr Kavan, Francine Aubin, Benoit Samson, John R. Goffin, Scott Berry, Tahir Abbas, Sheryl L. Koski, Alice Chia-chi Wei |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 40:3600-3600 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 3600 Background: Immune checkpoint blockade has limited activity in microsatellite-stable (MSS) or mis-match repair proficient (pMMR) CRC. Recent findings suggest that immunotherapy efficacy may be modulated by the presence of liver metastases. We conducted a retrospective analysis of the Canadian Cancer Trials Group (CCTG) CO.26 study to investigate the relationship between the presence of liver metastases and activity of immune checkpoint blockade. Methods: The CCTG CO.26 study was a randomized phase II study (NCT02870920). Pts with treatment refractory CRC were randomized to durvalumab, tremelimumab and best supportive care (BSC) or BSC alone in a 2:1 fashion. Treatment consisted of durvalumab (1500 mg) q 28 days and tremelimumab (75 mg) q 28 days for the first 4 cycles. The primary endpoint was overall survival (OS) and a two-sided p-value |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|